BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Following Complaint by Johnson & Johnson Vision Care, Inc. (JNJ) Court Orders Ocular Insight, Inc. to Discontinue Certain Advertising/Promotional Claims to Eye Care Professionals


9/18/2008 10:19:06 AM

JACKSONVILLE, Fla., Sept. 18 /PRNewswire/ -- Following a complaint filed in July 2008 by Johnson & Johnson Vision Care, Inc., a United States district court in New York has ordered, on both parties' consent, Ocular Insight, Inc. to permanently discontinue stating or communicating in its advertising or promotional materials or activities to eye care professionals for the company's Clear 58(R) contact lenses in the United States, any of the following claims:

"In the interest of patient safety, we felt an urgent need to address these misleading claims as quickly as possible," says Naomi Kelman, President, Americas, VISTAKON(R), Division of Johnson & Johnson Vision Care, Inc. "While Clear 58 has been 'cleared' for marketing by the FDA, it has not been 'approved' by the agency. Furthermore, the FDA does not perform the function of assessing whether a contact lens may be prescribed as a 'generic equivalent' lens."

And, according to Ms. Kelman, testing of the Clear 58 lens by Johnson & Johnson Vision Care shows that it is different from ACUVUE(R) 2 in material respects that would be expected to affect visual acuity, handling and/or comfort.

"Contact lens design and the manufacturing process are two key factors that differentiate contact lenses, explains Ms. Kelman. "The proprietary lens design and manufacturing process of all ACUVUE(R) Brand Contact Lenses are unique. In many cases, these differences in design and manufacture distinguish them from other contact lenses in areas such as comfort, eye health and vision. The Clear 58 product does not share the same characteristics that have long provided comfort and vision benefits to ACUVUE(R) 2 wearers and therefore may perform optically and physically differently on the eye.

"Doctors write prescriptions for the particular contact lens brand that best fits the overall comfort, eye health, and vision needs of the patient," she adds. "Contact lenses are medical devices that require a prescription, and contact lens wearers should never substitute a different brand than they presently have without the approval of their eye doctor."

ACUVUE(R) and VISTAKON(R) are trademarks of Johnson & Johnson Vision Care, Inc.

CONTACT: Gary Esterow of Vistakon, +1-908-216-5200, gester1@its.jnj.com

Web site: http://www.jnjvision.com/



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES